The medication cascade: how one drug leads to five

Understanding iatrogenic polypharmacy and its financial impact on claims

Published 3 April 2026

Introduction

The prescribing cascade, also known as iatrogenic polypharmacy, is a phenomenon where a medication prescribed for an initial indication creates an adverse effect that is subsequently treated with an additional medication, which then creates further adverse effects requiring additional prescriptions. This cascade mechanism transforms a single medication into a complex medication regimen, often escalating claim costs exponentially.

Research from major Australian and international healthcare systems indicates that approximately 25 to 35 percent of medications in polypharmacy patients are prescribed to manage adverse effects of other medications, rather than addressing primary disease. In workers compensation and personal injury claims where medication regimens are often complex, this percentage is substantially higher.

Classic Cascade Mechanisms

The Antihypertensive Cascade

Initial prescription: Amlodipine (calcium channel blocker) for blood pressure management. Adverse effect: peripheral ankle oedema (fluid retention in feet and legs). Secondary prescription: furosemide (loop diuretic) to manage swelling. Cascade effect: diuretic causes hypokalaemia (low potassium). Tertiary prescription: potassium supplementation. Additional effects: potassium supplementation causes GI upset. Quaternary prescription: proton pump inhibitor for reflux protection. Final cascade result: 4 medications for what began as single hypertension management.

Cost impact: amlodipine (AUD 15-25/month), furosemide (AUD 10-15/month), potassium supplement (AUD 20-30/month), proton pump inhibitor (AUD 15-25/month). Total: AUD 60-95 monthly vs. initial AUD 15-25. Five-fold cost increase within 6 to 12 months.

The Opioid Cascade

Initial prescription: Oxycodone for pain management. Adverse effects: constipation (occurs in 60 to 80 percent of opioid users). Secondary prescription: laxatives, stool softeners, or stronger agents (lactulose, macrogol). Cascade effect: inadequate bowel relief within 2 to 4 weeks. Tertiary prescription: additional bowel agents or prokinetics (metoclopramide). Additional effects: opioid dose escalation due to tolerance creates worsening constipation. Quaternary prescription: additional opioid-induced symptom management (sleep disturbance warrants hypnotics, anxiety warrants benzodiazepines or antidepressants). Final result: 5 to 7 medications for pain management and associated complications.

Cost and risk impact: medication complexity increases adverse event risk, drug interactions, and medication non-adherence. Deprescribing becomes increasingly difficult as cascade complexity increases.

The Antidepressant Cascade

Initial prescription: Sertraline for post-injury depression or anxiety. Adverse effects: sexual dysfunction (20 to 40 percent of users), weight gain (10 to 15 percent of users), insomnia (15 to 25 percent of users). Secondary prescriptions: sexual dysfunction warrants sildenafil or similar agents; weight gain warrants GLP-1 or weight loss interventions; insomnia warrants melatonin, benzodiazepines, or other hypnotics. Cascade complexity escalates when initial antidepressant inadequacy prompts dose increase or agent switching, compounding adverse effect burden. Final result: antidepressant plus 2 to 4 supporting medications.

Specific concern: benzodiazepine addition for sleep creates dual-agent CNS depression, increasing fall risk and cognitive impairment in injured claimants.

Why Cascades Go Undetected

Fragmented Prescriber Communication

Claimants typically see multiple prescribers: primary care physician, specialists (physiotherapist-referred pain clinic, psychiatrist, etc.), and often emergency department practitioners. Each prescriber views only their portion of the medication regimen, not the full cascade chain. A pain specialist prescribing oxycodone may be unaware that the GP already initiated multiple opioid adjunct medications.

Time Lapse Between Prescriptions

Medication cascades unfold over weeks to months. A prescriber initiating an antihypertensive in month 2 of a claim may not correlate ankle oedema appearing in month 4 to the initial prescription. The diuretic prescribed in month 4 is attributed to new clinical need rather than medication-induced complication.

Claimant Attribution Bias

Claimants frequently attribute medication-induced adverse effects to disease progression or injury sequelae rather than medication causation. A claimant experiencing sexual dysfunction from antidepressant therapy may attribute this to psychological distress from injury, rather than recognising the medication as causative. This misattribution perpetuates cascade prescribing.

Prescriber Habit and Guideline Adherence

Some prescribers adopt standardised regimen approaches (e.g., all hypertensive patients receive amlodipine plus a diuretic) without individualised assessment of whether cascade-prone medication combinations are necessary for a specific patient.

Cost Impact Analysis

Additional cost components not captured in medication cost alone: increased clinical consultations for cascade-related symptom management, hospitalisation for adverse events (medication interactions, falls from polypharmacy), and extended claim duration due to medication complexity impeding injury recovery.

Real-World Case Examples

Case 1: The Ankle Oedema Cascade

Workers compensation claimant, age 52, initial injury: lower back strain. Month 1: baseline hypertension diagnosed, amlodipine initiated (AUD 20/month). Month 3: peripheral oedema noted, furosemide initiated (AUD 12/month). Month 5: hypokalaemia detected on pathology, potassium supplementation added (AUD 25/month). Month 6: GI upset from potassium, ranitidine prescribed (AUD 18/month). Month 8: inadequate diuresis, spironolactone added (AUD 22/month). Total: 5 medications, AUD 97/month vs. initial AUD 20/month. Cost increase: 385 percent. 24-month claim cost: AUD 1,848 vs. AUD 480. Excess cost: AUD 1,368. Medication review at month 4 would have identified cascade risk and prompted deprescribing strategy.

Case 2: The Opioid Polypharmacy Cascade

CTP claimant, age 38, initial injury: motor vehicle accident with chronic pain syndrome. Month 1: oxycodone initiated for pain (AUD 45/month). Month 3: severe constipation develops, docusate and senna prescribed (AUD 20/month). Month 5: inadequate bowel management, lactulose added (AUD 15/month). Month 6: opioid dose escalated due to tolerance, pain inadequately controlled (AUD 65/month). Month 8: depression and insomnia develop, sertraline and zopiclone added (AUD 35/month). Month 10: drug interaction between opioids and sertraline causing sedation, claimant hospitalized for fall and head injury (AUD 8,000 event cost). Month 12: benzodiazepine added for anxiety (AUD 25/month). Total: 6 medications, AUD 205/month vs. initial AUD 45/month. Cost multiplier: 4.6x. Adverse event hospitalization: AUD 8,000. 24-month claim cost: AUD 4,920 plus hospitalization AUD 8,000 = AUD 12,920 vs. initial forecast AUD 1,080. Excess cost: AUD 11,840. Early medication review would have identified opioid inadequacy and considered alternative pain management approaches.

Cascade Identification and Intervention

Red Flag Identifiers

• Medication addition within 4 to 8 weeks of another medication initiation
• New medication indication that matches known adverse effect of existing medication
• Medication regimens with 5 or more chronic medications in claimants under age 60
• Sequential addition of agents addressing same organ system (e.g., multiple cardiovascular agents for oedema vs. hypertension)
• Claimant reporting new symptoms coinciding with recent medication initiation

Intervention Points

Deprescribing Challenges

Once a medication cascade has developed, reversal is complex. Simply removing the initial medication may fail to resolve cascade-induced adverse effects. For example, discontinuing amlodipine may not immediately resolve oedema if furosemide and potassium management are misaligned. Deprescribing requires coordinated prescriber involvement, close monitoring, and often sequential medication adjustments spanning weeks to months.

Claimant acceptance of deprescribing may also be compromised. Claimants perceiving a medication as beneficial (even if adverse-effect related) may resist discontinuation. Educating claimants about cascade mechanisms and deprescribing benefits requires time investment from medical or pharmacy teams.

Conclusion

Medication cascades represent significant but preventable cost drivers in insurance claims. Early identification of cascade-prone medication combinations and proactive prescriber communication can interrupt cascade development before multiple medications accumulate. For claims already experiencing cascade-driven polypharmacy, structured deprescribing approaches coordinated with clinical teams provide pathways to cost reduction and improved claimant outcomes.